Aarti Drugs Ltd

Aarti Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Drugs Ltd

₹ 485 1.01%
16 May - close price
aartidrugs.com BSE: 524348 NSE: AARTIDRUGS
About

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]

It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]

Key Points

Largest producer in World
Aarti Drugs Ltd. (ADL) is the largest producer of Fluoroquinolones group, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole in the world. It is one of the leading producers of Metformin in the world. [1]

Website BSE NSE
  • Market Cap ₹ 4,460 Cr.
  • Current Price ₹ 485
  • High / Low ₹ 646 / 430
  • Stock P/E 26.0
  • Book Value ₹ 139
  • Dividend Yield 0.21 %
  • ROCE 14.8 %
  • ROE 13.9 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 10.1% over past five years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 5.15% of profits over last 3 years
  • Promoter holding has decreased over last 3 years: -3.07%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
502 580 580 635 694 622 688 664 742 661 642 606 620
421 500 506 545 608 555 613 593 649 577 565 536 534
Operating Profit 81 80 74 90 86 67 74 71 94 84 76 70 86
OPM % 16% 14% 13% 14% 12% 11% 11% 11% 13% 13% 12% 12% 14%
1 2 0 7 3 0 0 1 1 1 1 2 1
Interest 4 4 5 5 6 7 8 9 9 9 8 8 9
Depreciation 12 12 12 13 13 13 13 13 12 13 13 13 14
Profit before tax 65 65 56 79 70 48 53 50 73 64 56 52 64
Tax % 21% 25% 24% 26% 22% 28% 27% 26% 23% 24% 30% 29% 26%
52 49 43 58 55 35 39 37 56 48 40 37 47
EPS in Rs 5.54 5.27 4.60 6.29 5.98 3.76 4.18 3.96 6.06 5.17 4.31 3.99 5.15
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
479 501 1,097 1,140 1,195 1,244 1,561 1,806 2,155 2,489 2,716 2,529
396 432 925 960 1,005 1,042 1,350 1,541 1,714 2,156 2,407 2,212
Operating Profit 83 69 172 180 190 202 211 266 440 333 309 316
OPM % 17% 14% 16% 16% 16% 16% 14% 15% 20% 13% 11% 13%
0 0 1 0 4 1 6 6 5 11 2 4
Interest 19 17 42 48 40 38 44 37 26 24 37 34
Depreciation 17 19 31 37 38 40 43 49 50 50 50 51
Profit before tax 47 33 100 95 116 125 131 185 369 270 224 236
Tax % 40% 29% 23% 28% 29% 34% 32% 24% 24% 24% 26% 27%
29 24 77 69 82 82 90 141 280 205 166 172
EPS in Rs 2.92 2.46 7.97 7.09 8.57 8.73 9.52 15.17 30.09 22.14 17.96 18.65
Dividend Payout % 21% 25% 41% 24% 3% 3% 3% 3% 8% 5% 6% 5%
Compounded Sales Growth
10 Years: %
5 Years: 10%
3 Years: 5%
TTM: -7%
Compounded Profit Growth
10 Years: %
5 Years: 14%
3 Years: -15%
TTM: 3%
Stock Price CAGR
10 Years: 26%
5 Years: 28%
3 Years: -14%
1 Year: 4%
Return on Equity
10 Years: %
5 Years: 20%
3 Years: 16%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 12 12 24 24 24 24 24 23 93 93 93 92
Reserves 134 151 284 333 376 432 520 629 820 944 1,100 1,190
189 267 448 483 480 546 507 389 351 543 609 564
84 93 248 261 311 388 405 535 502 629 620 587
Total Liabilities 419 523 1,004 1,102 1,191 1,389 1,455 1,576 1,766 2,208 2,421 2,432
208 248 448 493 581 602 625 644 665 690 676 847
CWIP 3 10 16 34 14 28 33 12 19 77 210 225
Investments 2 5 5 5 12 11 12 13 17 19 19 20
206 260 534 570 584 748 785 907 1,064 1,422 1,516 1,340
Total Assets 419 523 1,004 1,102 1,191 1,389 1,455 1,576 1,766 2,208 2,421 2,432

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
59 21 105 133 175 70 143 251 155 70 134 359
-30 -76 -107 -99 -107 -74 -62 -33 -72 -150 -164 -224
-24 53 1 -33 -68 4 -80 -215 -81 92 17 -136
Net Cash Flow 5 -3 -1 1 -0 0 1 2 2 13 -13 -1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 88 88 105 106 91 110 107 99 94 110 116 102
Inventory Days 77 103 82 86 100 132 86 102 117 115 101 106
Days Payable 60 73 83 90 94 123 85 104 93 103 94 93
Cash Conversion Cycle 105 118 104 103 97 119 109 97 118 123 123 115
Working Capital Days 106 134 98 102 97 122 105 87 110 122 128 116
ROCE % 20% 13% 18% 18% 17% 17% 21% 34% 21% 15%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
60.14% 60.12% 59.99% 59.83% 59.98% 59.77% 59.66% 59.57% 58.70% 58.57% 57.47% 57.13%
2.57% 2.21% 2.03% 2.07% 2.07% 1.94% 1.90% 1.94% 1.97% 2.33% 2.10% 2.56%
2.00% 2.12% 2.28% 2.69% 2.76% 3.16% 3.90% 4.09% 4.72% 5.32% 5.26% 5.99%
35.29% 35.55% 35.71% 35.41% 35.19% 35.11% 34.53% 34.39% 34.63% 33.78% 35.16% 34.30%
No. of Shareholders 1,77,9931,83,3441,95,4691,89,6071,86,6741,80,3031,73,2831,69,0901,62,4091,67,4461,70,4141,57,547

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls